Renata Mello Perez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Renata Mello Perez has a total of 234 co-authors. Here are the top co-authors by number of shared publications:
- Cristiane Alves Villela Nogueira
Department of Internal Medicine Federal University of Rio de Janeiro Rio de Janeiro Brazil
9 shared publications - Ronir Raggio Luiz
Public Health Institute, Federal University of Rio de Janeiro, Rio de Janeiro 21941-592, Brazil
9 shared publications - Daniella Braz Parente
Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
6 shared publications - Maria Lucia Gomes Ferraz
Universidade Federal de São Paulo
5 shared publications - Ana Carolina Cardoso
Hospital Universitário Clementino Fraga Filho, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
4 shared publications - Rosana Souza Rodrigues
Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
4 shared publications
Latest Publications
- Open Access
- 22 June 2026
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (12) , 6218-6238
Beyond morphology: functional imaging of the liver with gadoxetic acid-enhanced magnetic resonance imaging
Chronic liver diseases (CLD) are highly prevalent. Early diagnosis and staging of hepatic dysfunction are essential for optimal treatment decisions. While conventional imaging primarily evaluates morphology and focal liver lesions, gadoxetic acid (GA)-enhanced magnetic resonance imaging (MRI) provides additional functional information by assessing hepatocellular uptake and biliary excretion. Hepatocyte uptake depends largely on sinusoidal membrane transporters (OATP1B1/1B3), while excretion into bile canaliculi is mediated by MRP2. In liver dysfunction and cirrhosis, both processes may be impaired, resulting in measurable changes on hepatobiliary phase (HBP). This review summarizes the biological rationale, MRI protocol, and quantitative indices, including RLE, REI, HUI, rHUI, SIR, CUI, LSI, as well as the qualitative Functional Liver Imaging Score (FLIS). It also highlights key clinical applications, including prognostication in advanced CLD, preoperative risk stratification for post-hepatectomy liver failure, evaluation in the setting of embolization and locoregional therapies, and transplant assessment, along with emerging roles in metabolic dysfunction-associated steatotic liver disease. Finally, future directions are discussed, including T1 mapping and AI-based whole-liver quantification.
- 22 June 2026
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (12) , 6218-6238
Open AccessBeyond morphology: functional imaging of the liver with gadoxetic acid-enhanced magnetic resonance imaging
Chronic liver diseases (CLD) are highly prevalent. Early diagnosis and staging of hepatic dysfunction are essential for optimal treatment decisions. While conventional imaging primarily evaluates morphology and focal liver lesions, gadoxetic acid (GA)-enhanced magnetic resonance imaging (MRI) provides additional functional information by assessing hepatocellular uptake and biliary excretion. Hepatocyte uptake depends largely on sinusoidal membrane transporters (OATP1B1/1B3), while excretion into bile canaliculi is mediated by MRP2. In liver dysfunction and cirrhosis, both processes may be impaired, resulting in measurable changes on hepatobiliary phase (HBP). This review summarizes the biological rationale, MRI protocol, and quantitative indices, including RLE, REI, HUI, rHUI, SIR, CUI, LSI, as well as the qualitative Functional Liver Imaging Score (FLIS). It also highlights key clinical applications, including prognostication in advanced CLD, preoperative risk stratification for post-hepatectomy liver failure, evaluation in the setting of embolization and locoregional therapies, and transplant assessment, along with emerging roles in metabolic dysfunction-associated steatotic liver disease. Finally, future directions are discussed, including T1 mapping and AI-based whole-liver quantification.
- Open Access
- 9 March 2026
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (9) , 1-10
Agreement between single and multiple ROI strategies for hepatic T1 and ECV mapping in tetralogy of Fallot and Fontan circulation
Purpose: Native T1 and extracellular volume (ECV) mapping have emerged as promising tools for noninvasive assessment of hepatic congestion and fibrosis; however, optimal strategies for region-of-interest (ROI) selection remain uncertain. The aim was to evaluate the level of agreement between two methods for quantifying hepatic native T1 and ECV: single wide ROI versus multiple small ROIs, in patients with repaired tetralogy of Fallot (TOF) and Fontan circulation. Methods: This agreement study prospectively enrolled outpatients with repaired TOF or Fontan circulation between 2022 and 2025. All participants underwent hepatic evaluation using a cardiac Magnetic Resonance Imaging (MRI) protocol on a 3.0-T scanner. Native and post-contrast T1 mapping were acquired using Modified Look-Locker Inversion Recovery (MOLLI) sequences. Hepatic T1 and ECV were measured using (1) one wide ROI avoiding vascular structures and (2) three small circular ROIs placed in distinct parenchymal regions. Agreement was assessed using intraclass correlation coefficients (ICC) and survival-agreement plots. Results: A total of 61 patients was included (31 with TOF; 30 with Fontan circulation). Agreement between single-ROI and multiple-ROI strategies was excellent in TOF patients for both native T1 and ECV (ICC = 0.98), and good in patients with Fontan circulation for both parameters (ICC = 0.79). Survival-agreement analysis demonstrated that in TOF patients, all measurements differed by less than 80 ms for native T1 and less than 5% for ECV. In Fontan patients, 86% of measurements showed differences < 80 ms for native T1 and < 5% for ECV, reflecting greater hepatic heterogeneity while preserving overall concordance between ROI strategies. Conclusions: Hepatic native T1 and ECV measurements showed excellent agreement between single-wide and multiple-small ROI strategies in repaired TOF, supporting interchangeable use for longitudinal follow-up. In Fontan patients, concordance between methods was also good, as demonstrated by both ICC and survival-agreement analyses, indicating that either strategy remains feasible; nonetheless, the greater hepatic heterogeneity in this population warrants some caution when comparing measurements obtained with different ROI approaches. Graphical
- 9 March 2026
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (9) , 1-10
Open AccessAgreement between single and multiple ROI strategies for hepatic T1 and ECV mapping in tetralogy of Fallot and Fontan circulation
Purpose: Native T1 and extracellular volume (ECV) mapping have emerged as promising tools for noninvasive assessment of hepatic congestion and fibrosis; however, optimal strategies for region-of-interest (ROI) selection remain uncertain. The aim was to evaluate the level of agreement between two methods for quantifying hepatic native T1 and ECV: single wide ROI versus multiple small ROIs, in patients with repaired tetralogy of Fallot (TOF) and Fontan circulation. Methods: This agreement study prospectively enrolled outpatients with repaired TOF or Fontan circulation between 2022 and 2025. All participants underwent hepatic evaluation using a cardiac Magnetic Resonance Imaging (MRI) protocol on a 3.0-T scanner. Native and post-contrast T1 mapping were acquired using Modified Look-Locker Inversion Recovery (MOLLI) sequences. Hepatic T1 and ECV were measured using (1) one wide ROI avoiding vascular structures and (2) three small circular ROIs placed in distinct parenchymal regions. Agreement was assessed using intraclass correlation coefficients (ICC) and survival-agreement plots. Results: A total of 61 patients was included (31 with TOF; 30 with Fontan circulation). Agreement between single-ROI and multiple-ROI strategies was excellent in TOF patients for both native T1 and ECV (ICC = 0.98), and good in patients with Fontan circulation for both parameters (ICC = 0.79). Survival-agreement analysis demonstrated that in TOF patients, all measurements differed by less than 80 ms for native T1 and less than 5% for ECV. In Fontan patients, 86% of measurements showed differences < 80 ms for native T1 and < 5% for ECV, reflecting greater hepatic heterogeneity while preserving overall concordance between ROI strategies. Conclusions: Hepatic native T1 and ECV measurements showed excellent agreement between single-wide and multiple-small ROI strategies in repaired TOF, supporting interchangeable use for longitudinal follow-up. In Fontan patients, concordance between methods was also good, as demonstrated by both ICC and survival-agreement analyses, indicating that either strategy remains feasible; nonetheless, the greater hepatic heterogeneity in this population warrants some caution when comparing measurements obtained with different ROI approaches. Graphical
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (4)
Microeliminação da hepatite C em unidades de diálise: resultados do Registro Brasileiro para eliminação do HCV
Resumo Introdução: A infecção pelo vírus da hepatite C (HCV) é um desafio de saúde pública, especialmente em pacientes em diálise, que apresentam maior vulnerabilidade e risco de transmissão. A estratégia de microeliminação em subgrupos de alto risco é fundamental para atingir as metas globais da Organização Mundial da Saúde. Métodos: Trata-se de um estudo nacional de implementação, multicêntrico e prospectivo, fundamentado no Registro Brasileiro para Eliminação da Hepatite C em Unidades de Diálise. As 904 unidades de diálise ativas do país foram convidadas; 384 (42,5%) aderiram voluntariamente e, em cada uma, todos os pacientes elegíveis foram arrolados entre 2021 e 2024. Avaliou-se a cascata de cuidado: rastreamento sorológico (anti-HCV), confirmação virológica (RNA-HCV), tratamento com antivirais de ação direta (DAAs) e resposta virológica sustentada (SVR). Resultados: Foram avaliados 66.601 pacientes, com prevalência nacional de anti-HCV de 2,08%. A cobertura de testagem para RNA-HCV foi de 65,4%, com positividade de 64,2% entre os testados, resultando em uma prevalência ajustada de viremia de 1,34%. Dos pacientes com viremia detectada, 74,2% iniciaram o tratamento, 92,6% completaram o esquema e 93,3% alcançaram a SVR. As principais barreiras incluíram indisponibilidade de exames e óbito. Discussão: Os resultados demonstram que o Brasil possui indicadores robustos de eficácia terapêutica, situando o país em estágio avançado para a eliminação do HCV na população dialítica. No entanto, persistem gargalos operacionais na confirmação diagnóstica. Conclusão: A eliminação do HCV em unidades de diálise é uma meta factível no Brasil. O sucesso depende da manutenção do rastreio universal, do tratamento imediato dos casos confirmados e da integração contínua entre a nefrologia e a hepatologia.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (4)
Open AccessMicroeliminação da hepatite C em unidades de diálise: resultados do Registro Brasileiro para eliminação do HCV
Resumo Introdução: A infecção pelo vírus da hepatite C (HCV) é um desafio de saúde pública, especialmente em pacientes em diálise, que apresentam maior vulnerabilidade e risco de transmissão. A estratégia de microeliminação em subgrupos de alto risco é fundamental para atingir as metas globais da Organização Mundial da Saúde. Métodos: Trata-se de um estudo nacional de implementação, multicêntrico e prospectivo, fundamentado no Registro Brasileiro para Eliminação da Hepatite C em Unidades de Diálise. As 904 unidades de diálise ativas do país foram convidadas; 384 (42,5%) aderiram voluntariamente e, em cada uma, todos os pacientes elegíveis foram arrolados entre 2021 e 2024. Avaliou-se a cascata de cuidado: rastreamento sorológico (anti-HCV), confirmação virológica (RNA-HCV), tratamento com antivirais de ação direta (DAAs) e resposta virológica sustentada (SVR). Resultados: Foram avaliados 66.601 pacientes, com prevalência nacional de anti-HCV de 2,08%. A cobertura de testagem para RNA-HCV foi de 65,4%, com positividade de 64,2% entre os testados, resultando em uma prevalência ajustada de viremia de 1,34%. Dos pacientes com viremia detectada, 74,2% iniciaram o tratamento, 92,6% completaram o esquema e 93,3% alcançaram a SVR. As principais barreiras incluíram indisponibilidade de exames e óbito. Discussão: Os resultados demonstram que o Brasil possui indicadores robustos de eficácia terapêutica, situando o país em estágio avançado para a eliminação do HCV na população dialítica. No entanto, persistem gargalos operacionais na confirmação diagnóstica. Conclusão: A eliminação do HCV em unidades de diálise é uma meta factível no Brasil. O sucesso depende da manutenção do rastreio universal, do tratamento imediato dos casos confirmados e da integração contínua entre a nefrologia e a hepatologia.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (4)
Microelimination of hepatitis C in dialysis units: results from the Brazilian Registry for the elimination of HCV
Introduction: Hepatitis C virus (HCV) infection remains a major public health challenge, particularly among patients undergoing dialysis, who are disproportionately vulnerable and at increased risk of transmission. Micro-elimination strategies targeting high-risk subpopulations are a critical component for achieving the World Health Organization global HCV elimination goals. Methods: This national, multicenter, prospective implementation study was conducted within the framework of the Brazilian Registry for the Elimination of HCV in Dialysis Units. All 904 active dialysis units in the country were invited; 384 (42.5%) joined voluntarily, and, within each, all eligible patients were enrolled (census) between 2021 and 2024. The HCV cascade of care was evaluated, including serological screening (anti-HCV), virological confirmation (HCV-RNA), treatment with direct-acting antivirals (DAAs), and assessment of sustained virologic response (SVR). Results: A total of 66,601 patients were evaluated, yielding a national anti-HCV prevalence of 2.08%. HCV-RNA testing coverage reached 65.4%, with a positivity rate of 64.2% among those tested, resulting in an adjusted prevalence of active viremia of 1.34%. Among patients with detectable viremia, 74.2% initiated antiviral therapy, 92.6% completed treatment, and 93.3% achieved SVR. The main barriers identified along the cascade of care included limited availability of diagnostic tests and patient mortality. Discussion: These findings indicate that Brazil has achieved robust therapeutic effectiveness indicators, placing the country at an advanced stage toward HCV elimination within the dialysis population. Nonetheless, important operational gaps persist, particularly in diagnostic confirmation. Conclusion: Elimination of HCV in dialysis units is an achievable goal in Brazil. Sustained success depends on maintaining universal screening, ensuring prompt treatment initiation for confirmed cases, and strengthening continuous integration between services.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (4)
Open AccessMicroelimination of hepatitis C in dialysis units: results from the Brazilian Registry for the elimination of HCV
Introduction: Hepatitis C virus (HCV) infection remains a major public health challenge, particularly among patients undergoing dialysis, who are disproportionately vulnerable and at increased risk of transmission. Micro-elimination strategies targeting high-risk subpopulations are a critical component for achieving the World Health Organization global HCV elimination goals. Methods: This national, multicenter, prospective implementation study was conducted within the framework of the Brazilian Registry for the Elimination of HCV in Dialysis Units. All 904 active dialysis units in the country were invited; 384 (42.5%) joined voluntarily, and, within each, all eligible patients were enrolled (census) between 2021 and 2024. The HCV cascade of care was evaluated, including serological screening (anti-HCV), virological confirmation (HCV-RNA), treatment with direct-acting antivirals (DAAs), and assessment of sustained virologic response (SVR). Results: A total of 66,601 patients were evaluated, yielding a national anti-HCV prevalence of 2.08%. HCV-RNA testing coverage reached 65.4%, with a positivity rate of 64.2% among those tested, resulting in an adjusted prevalence of active viremia of 1.34%. Among patients with detectable viremia, 74.2% initiated antiviral therapy, 92.6% completed treatment, and 93.3% achieved SVR. The main barriers identified along the cascade of care included limited availability of diagnostic tests and patient mortality. Discussion: These findings indicate that Brazil has achieved robust therapeutic effectiveness indicators, placing the country at an advanced stage toward HCV elimination within the dialysis population. Nonetheless, important operational gaps persist, particularly in diagnostic confirmation. Conclusion: Elimination of HCV in dialysis units is an achievable goal in Brazil. Sustained success depends on maintaining universal screening, ensuring prompt treatment initiation for confirmed cases, and strengthening continuous integration between services.
- Open Access
- 7 September 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (7) , e70174
Mortality Outcomes of Combined Heart and Liver Transplantation and Isolated Heart Transplantation Following Fontan Procedures: A Systematic Review and Meta‐Analysis
Background: Fontan‐associated liver disease can progress to advanced fibrosis, raising the potential need for combined heart–liver transplantation (CHLT) in selected patients. However, the benefits of CHLT over isolated orthotopic heart transplantation (HT), particularly in terms of mortality, remain uncertain. In this systematic review, we compared mortality outcomes following CHLT versus HT in patients with Fontan circulation, with the aim of supporting clinical decision‐making. Methods: This systematic review was conducted according to the 2020 PRISMA guidelines and registered in PROSPERO. PubMed, Scopus, and Embase were searched. Studies examining HT or CHLT in patients with Fontan circulation that provided information about total and/or 1‐year mortality were included. Bias risks were assessed using the Newcastle‐Ottawa Scale. We used random‐ and fixed‐effect models, depending on heterogeneity, to estimate pooled effects. Results: Sixteen studies were included in this analysis. CHLT was associated with a lower mortality rate per patient‐year compared to HT (0.03 vs. 0.09; p < 0.01). However, after excluding studies in which transplantations were performed before the year 2000, the difference between groups was no longer statistically significant. One‐year mortality rates were also not significantly different between CHLT and HT (0.09 vs. 0.14; p = 0.28), with similar results observed after excluding pre‐2000 studies. Conclusion: Overall, this systematic review suggests that CHLT may result in mortality rates comparable to those of isolated HT. These findings support the consideration of CHLT in patients with concomitant liver disease and reinforce the importance of comprehensive liver evaluation in transplant candidates.
- 7 September 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (7) , e70174
Open AccessMortality Outcomes of Combined Heart and Liver Transplantation and Isolated Heart Transplantation Following Fontan Procedures: A Systematic Review and Meta‐Analysis
Background: Fontan‐associated liver disease can progress to advanced fibrosis, raising the potential need for combined heart–liver transplantation (CHLT) in selected patients. However, the benefits of CHLT over isolated orthotopic heart transplantation (HT), particularly in terms of mortality, remain uncertain. In this systematic review, we compared mortality outcomes following CHLT versus HT in patients with Fontan circulation, with the aim of supporting clinical decision‐making. Methods: This systematic review was conducted according to the 2020 PRISMA guidelines and registered in PROSPERO. PubMed, Scopus, and Embase were searched. Studies examining HT or CHLT in patients with Fontan circulation that provided information about total and/or 1‐year mortality were included. Bias risks were assessed using the Newcastle‐Ottawa Scale. We used random‐ and fixed‐effect models, depending on heterogeneity, to estimate pooled effects. Results: Sixteen studies were included in this analysis. CHLT was associated with a lower mortality rate per patient‐year compared to HT (0.03 vs. 0.09; p < 0.01). However, after excluding studies in which transplantations were performed before the year 2000, the difference between groups was no longer statistically significant. One‐year mortality rates were also not significantly different between CHLT and HT (0.09 vs. 0.14; p = 0.28), with similar results observed after excluding pre‐2000 studies. Conclusion: Overall, this systematic review suggests that CHLT may result in mortality rates comparable to those of isolated HT. These findings support the consideration of CHLT in patients with concomitant liver disease and reinforce the importance of comprehensive liver evaluation in transplant candidates.
- Open Access
- 11 August 2025
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22 (8) , 1257
A Resistance Training Program on Patients with Liver Cirrhosis: A Randomized Clinical Trial
Background: Cirrhosis represents an advanced stage of hepatic fibrosis, and the metabolic changes resulting from liver dysfunction can cause impairment in physical capacity and quality of life. This study aimed to evaluate the effect of 12 weeks of resistance exercise on inflammatory markers, oxidative stress, physical conditioning, and quality of life in patients with liver cirrhosis. Methods: A total of 38 patients paired in the exercise (EG) and control (CG) groups participated in this study. The EG submitted to two weekly sessions of a program composed of resistance exercises. We evaluated the inflammatory markers (IL-6, IL-10, and TNF-α), oxidative stress (carbonylated protein, total thiols, enzyme superoxide dismutase, and catalase activity), body composition, handgrip strength (HGS), total volume of training, cardiorespiratory capacity (VO2, VCO2, and VEpeak), exercise capacity, and quality of life. Results: Regarding the EG, when comparing the follow-up period to the baseline, significant differences (p < 0.05) were found in BMI, HGS, total training volume, cardiorespiratory capacity variables, the 6 min walk test, and quality of life. Improvements were observed, without significant differences, in the inflammatory profile, oxidative stress, and one of the markers of liver function. The CG showed a significant decrease (p < 0.05) in HGS and cardiorespiratory capacity after the intervention. Conclusions: In patients with liver cirrhosis, a resistance exercise program improved physical fitness and quality of life, without adverse events. In addition, it seems that this type of training can bring some benefit to the inflammatory profile and oxidative stress of this population.
- 11 August 2025
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22 (8) , 1257
Open AccessA Resistance Training Program on Patients with Liver Cirrhosis: A Randomized Clinical Trial
Background: Cirrhosis represents an advanced stage of hepatic fibrosis, and the metabolic changes resulting from liver dysfunction can cause impairment in physical capacity and quality of life. This study aimed to evaluate the effect of 12 weeks of resistance exercise on inflammatory markers, oxidative stress, physical conditioning, and quality of life in patients with liver cirrhosis. Methods: A total of 38 patients paired in the exercise (EG) and control (CG) groups participated in this study. The EG submitted to two weekly sessions of a program composed of resistance exercises. We evaluated the inflammatory markers (IL-6, IL-10, and TNF-α), oxidative stress (carbonylated protein, total thiols, enzyme superoxide dismutase, and catalase activity), body composition, handgrip strength (HGS), total volume of training, cardiorespiratory capacity (VO2, VCO2, and VEpeak), exercise capacity, and quality of life. Results: Regarding the EG, when comparing the follow-up period to the baseline, significant differences (p < 0.05) were found in BMI, HGS, total training volume, cardiorespiratory capacity variables, the 6 min walk test, and quality of life. Improvements were observed, without significant differences, in the inflammatory profile, oxidative stress, and one of the markers of liver function. The CG showed a significant decrease (p < 0.05) in HGS and cardiorespiratory capacity after the intervention. Conclusions: In patients with liver cirrhosis, a resistance exercise program improved physical fitness and quality of life, without adverse events. In addition, it seems that this type of training can bring some benefit to the inflammatory profile and oxidative stress of this population.
- Open Access
- 19 June 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (7)
Letter to the editor: Statins in esophageal variceal bleeding: What works in primary prophylaxis should not be presumed for secondary prophylaxis
- 19 June 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (7)
Open AccessLetter to the editor: Statins in esophageal variceal bleeding: What works in primary prophylaxis should not be presumed for secondary prophylaxis
- Open Access
- 21 May 2025
- Published by MDPI AG in Preprints.org
Strength Training Program on Patients with Liver Cirrhosis: A Randomized Clinical Trials
Background: Cirrhosis represents an advanced stage of hepatic fibrosis, and the metabolic changes resulting from liver dysfunction can cause impairment in physical capacity and quality of life. This study aimed to evaluate the effect of 12 weeks of resistance exercise on inflammatory markers, oxidative stress, physical conditioning, and quality of life in patients with liver cirrhosis. Methods: 38 patients paired in the exercise (EG) and control (CG) groups participated in the study. The EG submitted to 2 weekly sessions of a program composed of resistance exercises. We evaluated the inflammatory markers (IL-6, IL-10, and TNF-α), oxidative stress (carbonylated protein, total thiols, enzymes superoxide dismutase and catalase activity), body composition, handgrip strength (HGS), and total volume of training, cardiorespiratory capacity (VO2, VCO2 and VEpeak), exercise capacity and quality of life. Results: Regarding the EG, when comparing the follow-up moment to the baseline, significant differences (p<0.05) were found in BMI, HGS, total training volume, cardiorespiratory capacity variables, 6-min walk test, and quality of life. Improvements were observed, without significant differences, in the inflammatory profile, oxidative stress, and in one of the markers of liver function. The CG showed a significant decrease (p<0.05) in HGS and cardiorespiratory capacity after the intervention. Conclusions: In patients with liver cirrhosis, a resistance exercise program improved physical fitness and quality of life, without adverse events. Besides, it seems that this type of training can bring some benefit to the inflammatory profile and oxidative stress of this population.
- 21 May 2025
- Published by MDPI AG in Preprints.org
Open AccessStrength Training Program on Patients with Liver Cirrhosis: A Randomized Clinical Trials
Background: Cirrhosis represents an advanced stage of hepatic fibrosis, and the metabolic changes resulting from liver dysfunction can cause impairment in physical capacity and quality of life. This study aimed to evaluate the effect of 12 weeks of resistance exercise on inflammatory markers, oxidative stress, physical conditioning, and quality of life in patients with liver cirrhosis. Methods: 38 patients paired in the exercise (EG) and control (CG) groups participated in the study. The EG submitted to 2 weekly sessions of a program composed of resistance exercises. We evaluated the inflammatory markers (IL-6, IL-10, and TNF-α), oxidative stress (carbonylated protein, total thiols, enzymes superoxide dismutase and catalase activity), body composition, handgrip strength (HGS), and total volume of training, cardiorespiratory capacity (VO2, VCO2 and VEpeak), exercise capacity and quality of life. Results: Regarding the EG, when comparing the follow-up moment to the baseline, significant differences (p<0.05) were found in BMI, HGS, total training volume, cardiorespiratory capacity variables, 6-min walk test, and quality of life. Improvements were observed, without significant differences, in the inflammatory profile, oxidative stress, and in one of the markers of liver function. The CG showed a significant decrease (p<0.05) in HGS and cardiorespiratory capacity after the intervention. Conclusions: In patients with liver cirrhosis, a resistance exercise program improved physical fitness and quality of life, without adverse events. Besides, it seems that this type of training can bring some benefit to the inflammatory profile and oxidative stress of this population.
- 17 April 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (11) , 5223-5231
MRI-derived extracellular volume to assess liver fibrosis in patients with metabolic-associated steatotic liver disease
Purpose Metabolic associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease, and non-invasive fibrosis staging still represents a challenge. Our main objective was to estimate the degree of liver fibrosis in these patients using T1 mapping and the extracellular volume (ECV) by MRI in comparison with liver stiffness assessed by MR elastography (MRE). Methods In a single-center cross-sectional study, patients with MASLD were prospectively enrolled and underwent MRI with liver T1 mapping and ECV calculations. Groups with and without significant liver fibrosis assessed by MRE were compared with the Mann–Whitney test, chi-square test, and Fisher's exact test. Correlation analysis was conducted using Spearman’s test, and a receiver operating characteristic (ROC) curve was generated to assess the ability of ECV to differentiate between groups. Results This study evaluated 54 patients, 37% were men, with a mean age of 58.0 ± 12.0 years. Mild liver fibrosis (F0–F1) was present in 38 patients, and significant fibrosis (F2–F4) was detected in 16 patients. Patients with significant fibrosis presented higher native T1 (954 ± 126 vs. 820 ± 123; p < 0.001) and ECV (37.9% vs. 29.1%; p < 0.001) values than those with no/mild fibrosis. Liver stiffness was correlated with native T1 (r = 0.512, p < 0.001) and ECV (r = 0.443, p < 0.001). The native liver T1 and ECV differentiated patients with and without significant liver fibrosis on MRE (AUC = 0.85 and 0.84, respectively). Conclusion Native T1 and ECV show potential as an alternative method for the non-invasive staging of fibrosis in patients with MASLD, although further validation in larger cohorts is needed. Graphical abstract
- 17 April 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (11) , 5223-5231
MRI-derived extracellular volume to assess liver fibrosis in patients with metabolic-associated steatotic liver disease
Purpose Metabolic associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease, and non-invasive fibrosis staging still represents a challenge. Our main objective was to estimate the degree of liver fibrosis in these patients using T1 mapping and the extracellular volume (ECV) by MRI in comparison with liver stiffness assessed by MR elastography (MRE). Methods In a single-center cross-sectional study, patients with MASLD were prospectively enrolled and underwent MRI with liver T1 mapping and ECV calculations. Groups with and without significant liver fibrosis assessed by MRE were compared with the Mann–Whitney test, chi-square test, and Fisher's exact test. Correlation analysis was conducted using Spearman’s test, and a receiver operating characteristic (ROC) curve was generated to assess the ability of ECV to differentiate between groups. Results This study evaluated 54 patients, 37% were men, with a mean age of 58.0 ± 12.0 years. Mild liver fibrosis (F0–F1) was present in 38 patients, and significant fibrosis (F2–F4) was detected in 16 patients. Patients with significant fibrosis presented higher native T1 (954 ± 126 vs. 820 ± 123; p < 0.001) and ECV (37.9% vs. 29.1%; p < 0.001) values than those with no/mild fibrosis. Liver stiffness was correlated with native T1 (r = 0.512, p < 0.001) and ECV (r = 0.443, p < 0.001). The native liver T1 and ECV differentiated patients with and without significant liver fibrosis on MRE (AUC = 0.85 and 0.84, respectively). Conclusion Native T1 and ECV show potential as an alternative method for the non-invasive staging of fibrosis in patients with MASLD, although further validation in larger cohorts is needed. Graphical abstract
- Open Access
- 1 November 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (11)
Hepatopulmonary syndrome associated with common variable immunodeficiency: Is it reasonable to investigate?
- 1 November 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (11)
Open AccessHepatopulmonary syndrome associated with common variable immunodeficiency: Is it reasonable to investigate?